Pushing the Boundaries of Immunotherapy
One Delivery Platform, Limitless Possibilities
The unique versatility of our DPX platform allows packaging and delivery of a wide variety of immune-educating cargo, for example peptides, whole proteins, RNA, DNA, small molecules, and virus-like particles, to enable the development of novel immuno-therapeutics. Our lead DPX-enabled asset, MVP-S, represent the clinical validation of the potential of the DPX delivery platform to generate a durable and targeted immune response with limited adverse events.
We aim at replicating the MVP-S story with other bioactive molecules (peptides, proteins, mRNA, DNA, etc.); and we are actively seeking collaboration opportunities to potentially create DPX-enabled cancer vaccines with meaningful clinical efficacy.Partner With Us